Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Alice Tsang Shaw, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Alice Shaw and Rebecca Heist.
Connection Strength

2.208
  1. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021 May; 16(5):850-859.
    View in: PubMed
    Score: 0.245
  2. Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140.
    View in: PubMed
    Score: 0.208
  3. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
    View in: PubMed
    Score: 0.202
  4. Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 10; 12(10):e155-e157.
    View in: PubMed
    Score: 0.189
  5. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
    View in: PubMed
    Score: 0.179
  6. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245.
    View in: PubMed
    Score: 0.178
  7. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A. 2015 Feb 03; 112(5):1547-52.
    View in: PubMed
    Score: 0.162
  8. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. J Clin Oncol. 2011 May 20; 29(15_suppl):e18016.
    View in: PubMed
    Score: 0.125
  9. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
    View in: PubMed
    Score: 0.111
  10. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387.
    View in: PubMed
    Score: 0.055
  11. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions. Ann Oncol. 2018 10 01; 29(10):2092-2097.
    View in: PubMed
    Score: 0.052
  12. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
    View in: PubMed
    Score: 0.052
  13. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.051
  14. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018 05; 8(5):600-615.
    View in: PubMed
    Score: 0.050
  15. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.050
  16. Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies. J Thorac Oncol. 2016 11; 11(11):2022-2026.
    View in: PubMed
    Score: 0.045
  17. Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. JAMA Oncol. 2016 Apr; 2(4):541-3.
    View in: PubMed
    Score: 0.044
  18. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
    View in: PubMed
    Score: 0.040
  19. Genotyping lung cancer is an investment in the future. J Clin Oncol. 2014 Nov 01; 32(31):3576-7.
    View in: PubMed
    Score: 0.039
  20. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1602-8.
    View in: PubMed
    Score: 0.034
  21. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
    View in: PubMed
    Score: 0.032
  22. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
    View in: PubMed
    Score: 0.031
  23. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.